Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Nippon Shinyaku
Nippon Shinyaku
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Viltepso
Viltolarsen
2020-08-12
2031
Duchenne muscular dystrophy
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Viltolarsen
duchenne muscular dystrophy
,
muscular dystrophies
Aglatimagene besadenovec
prostatic hyperplasia
,
hyperplasia
Ademetionine
essential thrombocythemia
,
polycythemia vera
,
primary myelofibrosis
,
thrombocytosis
,
polycythemia
,
duchenne muscular dystrophy
,
muscular dystrophies
Sodium chloride
duchenne muscular dystrophy
,
muscular dystrophies
Sodium lactate
duchenne muscular dystrophy
,
muscular dystrophies
ILGINATINIB
essential thrombocythemia
,
polycythemia vera
,
primary myelofibrosis
,
thrombocytosis
,
polycythemia
Microcrystalline cellulose
duchenne muscular dystrophy
,
muscular dystrophies
NS-018
essential thrombocythemia
,
polycythemia vera
,
primary myelofibrosis
,
thrombocytosis
,
polycythemia
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use